StockNews.AI
FBIO
StockNews.AI
1 min

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortress Biotech Inc. - FBIO

1. Pomerantz LLP is investigating Fortress Biotech for potential securities fraud. 2. Fortress received a Complete Response Letter from the FDA regarding CUTX-101. 3. The FDA's letter cited cGMP deficiencies at the manufacturing facility. 4. Following the FDA news, Fortress's stock fell by 30.81% to $2.56. 5. Investors are advised to consider potential legal actions against Fortress.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The stock's significant decline indicates severe market concern following FDA action.

How important is it?

The potential for fraud claims and regulatory challenges will likely keep pressure on FBIO's stock.

Why Short Term?

Immediate concerns arise from the FDA's actions, impacting investor sentiment quickly.

Related Companies

CUTX
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Fortress Biotech Inc. ("Fortress" or the "Company") (NASDAQ: FBIO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Fortress and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On October 1, 2025, Fortress and its subsidiary, Cyprium Therapeutics, Inc., announced receipt of a Complete Response Letter ("CRL") from the U.S. Food and Drug Administration in connection with the New Drug Application for CUTX-101.  Fortress disclosed that the "CRL noted cGMP [Current Good Manufacturing Practice] deficiencies had been observed at the facility where CUTX-101 is manufactured."  On this news, Fortress's stock price fell $1.14 per share, or 30.81%, to close at $2.56 per share on October 1, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes.   CONTACT:Danielle PeytonPomerantz LLP[email protected]646-581-9980 ext. 7980 SOURCE Pomerantz LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News